Miraculins Re-Appoints Pear Healthcare Solutions to Distribute Scout DS(R) to Canadian Retail Pharmacy/Grocery Market

Miraculins Re-Appoints Pear Healthcare Solutions to Distribute Scout DS(R) to 
Canadian Retail Pharmacy/Grocery Market 
WINNIPEG, MANITOBA -- (Marketwired) -- 08/16/13 -- Miraculins Inc.
(TSX VENTURE:MOM), ("Miraculins" or the "Company") a medical
diagnostic company focused on acquiring, developing and
commercializing diagnostic and risk assessment technologies for unmet
clinical needs, announces today that it has re-appointed Pear
Healthcare Solutions Inc. ("Pear"), a leading provider of in-pharmacy
health screening and education services, as the distributor for the
SCOUT DS(R) Non-Invasive Diabetes Test Technology to the Canadian
retail pharmacy/grocery market. Pear is also the Company's Canadian
distributor for the PreVu(R) Non-Invasive Skin Cholesterol
Point-of-Care (POC) Test to the same market segment.  
Prior to Miraculins' acquisition of the SCOUT DS(R), Pear was
appointed as Canadian distributor for the technology by VeraLight,
Inc. (its previous owner) and had successfully established pilots for
this ground-breaking, non-invasive diabetes test. These included
localized trials with national and regional brand pharmacy/grocery
retailers including Zellers, Costco, Rexall, and PharmaSave. In
addition, Pear has designed a comprehensive CE Module (Continuing
Education) on non-invasive diabetes testing, which has been
recognized by the Canadian Pharmacists Association as accredited
programming, and has also developed a special preparatory program to
ready pharmacists prior to their taking the Certified Diabetes
Educator exam. These programs are offered through Pear's Health
eLearning initiative and online learning portal, which allows
pharmacists to conveniently participate in accredited CEs on such
topics as cardiovascular disease, diabetes and osteoporosis. As a
result, Pear's commitment to national diabetes education and
preventive testing has been significant and unparalleled among
service providers to the industry. 
"Pear has provided excellent representation for Miraculins in
establishing select pilots for PreVu(R), and has clearly demonstrated
its ability to do the same for the SCOUT DS(R) in the Canadian retail
pharmacy sector," said Paul Moreau, Vice President, Sales and
Marketing of Miraculins Inc. "As we move forward with our piloting
and beyond, we are confident Pear has the industry relationships and
segment expertise necessary to build broader distribution for our
non-invasive testing technologies."  
"Based on the positive responses we have received during the pilots
from both retailers and consumers, we are excited about the potential
for national distribution of these non-invasive technologies, and we
look forward to continuing to work in partnership with Miraculins
towards achieving this goal," said Mark Doyle, Vice President of
Sales and Marketing for Pear Healthcare Solutions Inc. 
About Pear Healthcare Solutions 
Pear Healthcare Solutions is a privately held company specializing in
the development and implementation of programs to address the
evolving needs of pharmacists in their expanding role of providing
healthcare and disease management services. Pear Healthcare Solutions
offers a number of innovative medical devices and professional
education programs that help pharmacies connect with their patients,
improving their health and wellness. Pear provides distribution,
training and support/education services. For more information visit
www.pearhealthcare.com. 
About Miraculins Inc. 
Miraculins is a medical diagnostic company focused on acquiring,
developing and commercializing non-invasive technologies for unmet
clinical needs. A significant number of promising diagnostic
opportunities remain un-commercialized because of the sizable gap
between the discovery stage, when research institutions are typically
involved, and the commercialization stage, when the larger commercial
enterprises become interested. Miraculins has direct experience in
bridging this gap. The Company's PreVu(R) technology is a
revolutionary new coronary artery disease risk assessment technology
that measures cholesterol levels in a patient's skin non-invasively,
painlessly and without the need for fasting. The Company's SCOUT
DS(R) system, is the first non-invasive diabetes screening system
designed to provide a highly sensitive and convenient method for
screening for pre-diabetes and type 2 diabetes based on the presence
of diabetes-related biomarkers found in skin. Unlike current
screening methods, a SCOUT DS(R) test requires no blood draw, no
fasting, and no waiting for a lab result. The product has been used
and validated in thousands of patients around the world. The
Company's preeclampsia program is partnered with Alere Inc., one of
the world's largest diagnostic companies. For more information visit
www.miraculins.com. 
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.  
Caution Regarding Forward-Looking Information 
Certain statements contained in this press release constitute
forward-looking information within the meaning of applicable Canadian
provincial securities legislation (collectively, "forward-looking
statements"). These forward-looking statements relate to, among other
things, our objectives, goals, targets, strategies, intentions,
plans, beliefs, estimates and outlook, including, without limitation,
our anticipated future operating results, and can, in some cases, be
identified by the use of words such as "believe," "anticipate,"
"expect," "intend," "plan," "will," "may" and other similar
expressions. In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances are forward-looking statements.  
These statements reflect management's current beliefs and are based
on information currently available to management. Certain material
factors or assumptions are applied in making forward-looking
statements, and actual results may differ materially from those
expressed or implied in such statements. Important factors that could
cause actual results to differ materially from these expectations
include, among other things: Miraculins' early stage of development,
lack of product revenues and history of operating losses,
uncertainties related to clinical trials and product development,
rapid technological change, uncertainties related to forecasts,
competition, potential product liability, additional financing
requirements and access to capital, unproven markets, supply of raw
materials, income tax matters, management of growth, partnerships for
development and commercialization of technology, effects of insurers'
willingness to pay for products, system failures, dependence on key
personnel, foreign currency risk, risks related to regulatory matters
and risks related to intellectual property and other risks detailed
from time to time in Miraculins' filings with Canadian securities
regulatory authorities, as well as Miraculins' ability to anticipate
and manage the risks associated with the foregoing. Additional
information about these factors and about the material factors or
assumptions underlying such forward-looking statements may be found
in the body of this news release. Miraculins cautions that the
foregoing list of important factors that may affect future results is
not exhaustive. When relying on Miraculins' forward-looking
statements to make decisions with respect to Miraculins investors and
others should carefully 
consider the foregoing factors and other
uncertainties and potential events.  
These risks and uncertainties should be considered carefully and
prospective investors should not place undue reliance on the
forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management
believes to be reasonable assumptions, Miraculins cannot provide
assurance that actual results will be consistent with these
forward-looking statements. Miraculins undertakes no obligation to
update or revise any forward-looking statement.  
PreVu(R) and SCOUT DS(R) are registered trademarks of Miraculins Inc.
All Rights Reserved. 2013.
Contacts:
Miraculins Inc.
Paul Moreau
Vice President, Sales and Marketing
204-478-5603
204-453-1596 (FAX) 
Miraculins Inc.
Christopher J. Moreau
President & CEO
204-477-7599
204-453-1596 (FAX)
info@miraculins.com
www.miraculins.com
 
 
Press spacebar to pause and continue. Press esc to stop.